SAF Holland SA SFQ Valuation Ratios and Share Stats

Year End December 30 2023	2016	2017	2018	2019	2020	2021	2022	2023
	EUR (€)	EUR (€)	EUR (€)	EUR (€)	EUR (€)	EUR (€)	EUR (€)	EUR (€)
Return on Assets (%)	4.65	4.263	4.875	0.918	1.452	3.798	4.862	5.075
Return on Equity (%)	14.926	14.157	15.201	2.76	4.461	10.941	15.037	17.427
Return on Invested Capital (%)	11.671	8.364	13.818	8.709	8.174	11.204	15.495	22.22
Operating Margin (%)	7.74	6.42	6.024	2.733	3.205	5.829	6.953	7.994
Net Profit Margin (%)	4.245	3.766	3.702	0.699	1.438	2.947	3.903	3.795
Book Value Per Share	2.169	2.348	1.471	1.324	0.667	1.489	2.351	0.537
Earnings Per Share	0.975	0.945	1.061	0.198	0.152	0.405	0.673	0.88
Cash Per Share	7.596	6.146	3.415	2.89	1.883	1.82	2.682	2.713
Working Capital Per Share	9.99	8.488	7.274	2.716	2.798	3.381	3.165	5.137
Operating Profit Per Share	5.098	5.155	5.332	5.381	2.297	2.797	3.362	5.369
EBIT Per Share	1.432	1.239	1.415	0.533	0.213	0.691	0.975	1.341
EBITDA Per Share	1.432	1.239	1.415	0.533	0.213	0.691	0.975	1.341
Free Cash Flow Per Share	1.468	1.451	1.759	0.423	-0.078	0.356	0.863	1.144

Year End December 30 2023	2016	2017	2018	2019	2020	2021	2022	2023
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Quick Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory Turnover (Days)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Play Episode

7min

Proactive - Interviews for investors

Mag Mile Capital accelerates growth with $80M in deals, AI-Powered expansion strategy

Mag Mile Captial CEO Rushi Shah joined Steve Darling from Proactive to discuss the company’s rapid expansion in 2024, highlighted by over $80 million in commercial real estate transactions in just the past two months and an active pipeline of $250 million. Recent closings include a $14.5 million deal in Rochester, New York, and a $13 million transaction in Harker Heights, Texas. Shah emphasized Mag Mile’s transformation into a tech-driven finance company, integrating AI and machine learning to streamline underwriting and deal execution. The firm’s proprietary Cap Logic platform is designed to reduce transaction cycle times by up to 50 times, significantly improving efficiency. Looking ahead, Shah outlined his vision to scale Mag Mile into a $1 billion company through strategic acquisitions and a roll-up strategy, consolidating service providers under the firm’s expanding umbrella. “We are aggressively employing a roll-up strategy,” he noted, reinforcing the company’s commitment to growth. With ample capital, strong demand for real estate financing, and advanced technology integration, Mag Mile Capital is well-positioned to capitalize on industry trends and redefine commercial real estate finance. #proactiveinvestors #magmilecapitalinc #otcqb #mmcp #capital #RealEstateFinance #AIinFinance #CommercialLoans #CRE #Investment #RealEstateInvesting #ProactiveInvestors #CapLogic #Fintech

Proactive - Interviews for investors

4GLOBAL CEO on successful North America pivot and growth plans

4GLOBAL PLC CEO Eloy Mazon talked with Proactive's Stephen Gunnion about the company’s strategic growth, focusing on its expansion into the North American market, following the release of a trading update for the year to end-March 2025. Mazon emphasised that 4GLOBAL is not focused on short-term gains but on building a high-quality, scalable business. He explained that breaking into North America—a challenging but lucrative market—has been a key transition, and the company has made strong progress. Revenue in the region grew by 145%, reaching £1.6 million by February. The company has also shifted its revenue model, increasing repeatable, high-margin contracts from 60% to 81% of total revenue. Mazon highlighted that this shift enhances long-term growth, revenue predictability, and business resilience. Meanwhile, 4GLOBAL has reduced its focus on lower-margin operations in the Middle East, with revenue there dropping from £2.5 million to £400,000. In the UK and Europe, revenue remains steady at £3.1 million, with strong potential for future growth. Mazon stressed that 4GLOBAL has now laid the groundwork for scalable expansion and is positioned for sustainable long-term success. For more exclusive interviews and insights, subscribe to Proactive's YouTube channel, hit the like button, and turn on notifications for updates. #4GLOBAL #Investment #StockMarket #BusinessGrowth #NorthAmerica #MarketExpansion #CEOInterview #TechStocks #InvestorNews #ProactiveInvestors

Proactive - Interviews for investors

Crucial Innovations CEO JP Doran on unique proposition and growth strategy

Crucial Innovations Corp CEO Jon-Paul Doran talked with Proactive's Stephen Gunnion about the company’s expansion. The US-based firm, soon to be quoted on the OTC markets, operates a vertically integrated business with cultivation facilities in South Africa and a dispensary in the UK. Doran highlighted the company’s seed-to-sale model, which ensures control over quality and supply. He explained that their proprietary genetics provide an edge in the medicinal market, enabling precision medicine for patients. With a low-cost production base in South Africa and a growing European and UK market focus, the company is positioned for long-term growth. Discussing the decision to list in the US, Doran cited higher investor interest and market potential compared to the UK. He expects Crucial Innovations to start trading on the OTCQB by mid-to-late April, with a plan to uplist to the OTCQX and eventually Nasdaq. The company also has an aggressive acquisition strategy, aiming to acquire high-efficiency operators to boost its net asset value, revenue, and human capital. “We want to be a driver of consistent quality,” Doran emphasized, highlighting South Africa’s progressive stance and the expertise of its cultivation specialists. Watch the full interview to learn more about Crucial Innovations’ vision and upcoming milestones. Don't forget to like, subscribe, and turn on notifications for more updates from Proactive! #CrucialInnovations #OTCMarkets #Investing #CannabisIndustry #JPdoran #SouthAfrica #SeedToSale #OTCQB #OTCQX #Nasdaq #ProactiveInvestors

Proactive - Interviews for investors

Race Oncology’s RC220 trial gets green light

Race Oncology Ltd chair Peter Smith talked with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its clinical trial for RC220, a new formulation of bisantrene. Smith explained that the trial aims to establish the safety of RC220 both as a standalone treatment and in combination with doxorubicin, a commonly used chemotherapy drug. "What we’ll be seeking to achieve is establishing the maximum tolerated dose for the combination of the two drugs together," he said. The study will also investigate whether RC220 can reduce doxorubicin’s known toxicity to the cardiovascular system. Smith highlighted that doxorubicin can cause permanent heart damage, potentially reducing patient lifespan by the equivalent of a decade. The company aims to demonstrate that RC220 can enhance anti-cancer effects while mitigating heart-related side effects. The trial will be conducted in multiple phases, beginning in Australia, with expansion planned into Korea and Hong Kong later in the year. Smith noted that the Cancer Care Foundation is playing a role in patient support and accessibility. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future updates. #RaceOncology #CancerResearch #ClinicalTrial #Biotech #Oncology #RC220 #Doxorubicin #CardioProtection #Pharma #MedicalResearch #CancerTreatment

Market Cap	799.85M
Price to Earnings Ratio	0
Price to Sales Ratio	0
Price to Cash Ratio	0
Price to Book Ratio	0
Dividend Yield	487.94%

Shares Outstanding	45.39M
Average Volume (1 week)	16.73k
Average Volume (1 Month)	17.02k
52 Week Change	-5.33%
52 Week High	19.74
52 Week Low	12.80

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover